Dr. Brian Morray: Harmony TPV Demonstrates Safe and Sustained Valve Function

Recently, mid-term results from an expanded cohort of Harmony transcatheter pulmonary patients were presented at SCAI 2024. The results show an excellent safety profile, with no new deaths, thrombosis, major stent fracture, or arrhythmia between 2 and 3 years of follow-up. The data demonstrate sustained valve function with no more than mild pulmonary regurgitation (PR) in all but one patient at 3 years. Positive effects on right ventricular (RV) remodeling were observed with improved RV stroke volume and RV end-diastolic volume through two years. The Harmony TPV system was designed to treat patients with right ventricular outflow tract (RVOT) anomalies in native or surgically repaired patients with severe pulmonary valve regurgitation, a condition where blood leaks back into the right lower chamber of the heart after being pumped into the lungs. The Harmony TPV provides these patients with a minimally invasive treatment alternative. DocWire News spoke with Dr. Brian Morray, principal investigator of this study, to find out more about the valve's promising performance.